BBIO Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -143.55% compared to BridgeBio Pharma's net margin of -10220.14%. BridgeBio Pharma's return on equity of -- beat Cytokinetics's return on equity of --.

BridgeBio Pharma has a consensus price target of $58.78, signalling upside risk potential of 76.3%. On the other hand Cytokinetics has an analysts' consensus of $73.45 which suggests that it could grow by 140.5%. Given that Cytokinetics has higher upside potential than BridgeBio Pharma, analysts believe Cytokinetics is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.149, which suggesting that the stock is 14.912% more volatile than S&P 500. In comparison Cytokinetics has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.173%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are larger than Cytokinetics quarterly revenues of $1.6M. BridgeBio Pharma's net income of -$167.4M is lower than Cytokinetics's net income of -$161.4M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 49.44x versus 184.16x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -143.55% compared to BridgeBio Pharma's net margin of -53.36%. BridgeBio Pharma's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -49.57%.

BridgeBio Pharma has a consensus price target of $58.78, signalling upside risk potential of 76.3%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $423.14 which suggests that it could grow by 58.15%. Given that BridgeBio Pharma has higher upside potential than Madrigal Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Madrigal Pharmaceuticals.

BridgeBio Pharma has a beta of 1.149, which suggesting that the stock is 14.912% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.906, suggesting its less volatile than the S&P 500 by 190.598%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. BridgeBio Pharma's net income of -$167.4M is lower than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 49.44x versus 18.37x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -143.55% compared to BridgeBio Pharma's net margin of 21.63%. BridgeBio Pharma's return on equity of -- beat Pfizer's return on equity of 8.72%.

BridgeBio Pharma has a consensus price target of $58.78, signalling upside risk potential of 76.3%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 26.5%. Given that BridgeBio Pharma has higher upside potential than Pfizer, analysts believe BridgeBio Pharma is more attractive than Pfizer.

BridgeBio Pharma has a beta of 1.149, which suggesting that the stock is 14.912% more volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.29% to investors and pays a quarterly dividend of $0.43 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are smaller than Pfizer quarterly revenues of $13.7B. BridgeBio Pharma's net income of -$167.4M is lower than Pfizer's net income of $3B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 49.44x versus 2.13x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -143.55% compared to BridgeBio Pharma's net margin of --. BridgeBio Pharma's return on equity of -- beat Plus Therapeutics's return on equity of --.

BridgeBio Pharma has a consensus price target of $58.78, signalling upside risk potential of 76.3%. On the other hand Plus Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 3188.74%. Given that Plus Therapeutics has higher upside potential than BridgeBio Pharma, analysts believe Plus Therapeutics is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.149, which suggesting that the stock is 14.912% more volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.878, suggesting its less volatile than the S&P 500 by 12.185%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are larger than Plus Therapeutics quarterly revenues of --. BridgeBio Pharma's net income of -$167.4M is lower than Plus Therapeutics's net income of -$2.9M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 49.44x versus 0.37x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.